CAL-130 is a potent and selective inhibitor of PI3Kδ and PI3Kγ, with IC50 values of 1.3 nM and 6.1 nM, respectively, and shows significantly less activity against PI3Kβ (IC50 = 56 nM) and PI3Kα (IC50 = 115 nM). It does not inhibit other critical intracellular signaling pathways such as p38 MAPK or insulin receptor tyrosine kinase. In vivo, CAL-130 demonstrates significant therapeutic efficacy in a mouse model of T-cell acute lymphoblastic leukemia (T-ALL), markedly extending median survival (45 days vs. 7.5 days in controls) following short-term oral administration (10 mg/kg every 8 hours for 7 days).